October 12, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for April 30, 2008 Subscribe to this News Feed  
 

LegalView Updates Its Baxter Heparin Information Portal With News of Ongoing United States and China Heparin Contamination Controversy

Download this press release as an Adobe PDF document.

LegalView recently updated its Heparin information portal on the latest news regarding the contaminated batch of Heparin, which may have sickened hundreds and caused the death of up to 90 individuals. U.S. officials have sourced the contamination to a manufacturing plant in China, but Chinese officials insist the contamination occurred in the United States.

Denver, CO (PRWEB) April 30, 2008 -- LegalView recently updated its Heparin information portal to include the latest information on the Baxter Heparin recall that may have caused severe allergic reactions and the deaths of more than 80 patients. Investigating the source of contamination has led U.S. officials to a manufacturing plant in China, where over-sulfated chrondroitin sulfate was reportedly chemically altered to simulate Heparin. The use of the compound would have allowed for a less expensive production of the original Heparin, however, the U.S. Food and Drug Administration (FDA) never approved the compound for use in Heparin. Individuals who may have been victim of the tainted Heparin batch should contact a pharmaceutical attorney for details on the development of a potential Heparin lawsuit.

Heparin is an anticoagulant that is often used during surgical procedures such as kidney dialysis or heart surgery. It thins the blood in order to avoid the development of deep vein thrombosis, which can be deadly in surgery. Heparin is derived from pig intestines and has been imported, predominately from China, since the 1930s.

Manufacturers of the drug, Baxter International Inc., issued the Heparin recall in January but have since been battling with Chinese regulators who claim the Baxter Heparin contamination occurred at the Baxter New Jersey factory. Chinese officials have said that the Heparin was manufactured and sent to several other countries who had not reported the side effects that the Baxter Heparin victims did. However, the FDA claims, upon the results of their investigation, that the tainted Heparin went to 12 countries. The FDA also explained that the side effects did occur in individuals in Germany, but were more prevalent in the United States because of the practice among U.S. surgeons to use more Heparin in patients.

For more information on this or other pharmaceutical complications, visit LegalView's many information portals, where individuals can find information on a range of issues such as details of a potential Vytorin Lawsuit, mesothelioma litigation or construction accidents.

Vytorin is a prescription medication that can be used to treat dyslipidemia, occurring when the amount of lipids in the bloodstream becomes imbalanced, thus increasing the amount of bad cholesterol among an individual. A study that was released evaluating the drug found that the drug was actually less beneficial than generic versions, despite being more than three times as expensive. To learn about a Vytorin lawsuit contact a pharmaceutical law firm in your area.

Individuals needing help locating mesothelioma lawyers or a construction accident attorney can use the mesothelioma or construction accident practice areas.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

###

Trackback URL: http://www.prweb.com/pingpr.php/Q3Jhcy1aZXRhLVNpbmctSG9yci1GYWx1LVplcm8=


See the original story at: http://www.prweb.com/releases/2008/04/prweb897454.htm
Other Releases by this Member
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Katie Kelley
LegalView
720-771-3246
Email us Here
Alan Haburchak
Visit Our Site
720-771-3246
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright